Skip to main content

Advertisement

SpringerLink
Log in

Evaluation eines dominant-negativen rekombinanten Herpes-simplex-Virus (HSV) Typ 1 als Impfstoff gegen Herpes genitalis bei Mäusen und Meerschweinchen

Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs

  • In der Diskussion
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Herpes genitalis wird durch Herpes-simplex-Viren (HSV) hervorgerufen und gehört zu den häufigsten Geschlechtskrankheiten weltweit. Bislang steht noch kein effektiver und sicherer Impfstoff gegen HSV zur Verfügung. CJ9-gD ist ein absolut replikationsdefektes rekombinantes HSV-1, das in Koinfektionen die Replikation von Wildtyp-HSV-1/-2 blockiert (dominant-negativer Effekt) und eine frühe und starke Expression des HSV-Hauptantigens Glykoprotein D gewährleistet. Die Immunisierung mit CJ9-gD induziert starke und lang anhaltende humorale und TH1-gewichtete zelluläre Immunantworten gegen HSV-1 und HSV-2 bei Mäusen und schützt diese deutlich gegen genitale Infektionen mit HSV-1 oder HSV-2. Bei Meerschweinchen erzielt die Immunisierung mit CJ9-gD einen signifikanten Schutz gegen primäre und rezidivierende genitale HSV-2-Infektion sowie eine Reduktion der latenten Infektion.

Abstract

Genital herpes caused by herpes simplex virus (HSV) is one of the most common sexually transmitted diseases worldwide. Currently, no safe and effective vaccine against HSV is available. CJ9-gD is a completely replication-defective HSV-1 recombinant which inhibits replication of wild-type HSV-1/-2 in co-infected cells (dominant-negative effect). Moreover, it expresses high levels of HSV-1 major antigen glycoprotein D (gD). Immunization with CJ9-gD induces strong and long-lasting humoral and Th1-like cellular immune responses against both HSV-1 and HSV-2 in mice protecting immunized animals significantly against genital challenge with HSV-1 or HSV-2. Guinea pigs immunized with CJ9-gD were significantly protected against primary and recurrent HSV-2 genital disease and latent infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Augustinova H, Hoeller D et al (2004) The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol 78(11):5756–5765

    Article  CAS  PubMed  Google Scholar 

  2. Brans R, Akhrameyeva NV et al (2009) Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. J Invest Dermatol 129(10):2470–2479

    Article  CAS  PubMed  Google Scholar 

  3. Brans R, Eriksson E et al (2008) Immunization with a dominant-negative herpes simplex virus (HSV) type 1 protects against HSV-1 skin disease in guinea pigs. J Invest Dermatol 128(12):2825–2832

    Article  CAS  PubMed  Google Scholar 

  4. Brans R, Yao F (2010) Immunization with a dominant-negative recombinant herpes simplex virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol 10:163

    Article  PubMed  Google Scholar 

  5. Corey L, Langenberg AG et al (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4):331–340

    Article  CAS  PubMed  Google Scholar 

  6. Freeman EE, Orroth KK et al (2007) Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in Sub-Saharan African HIV epidemics. Sex Transm Infect 83(Suppl 1):i17–i24

    Article  PubMed  Google Scholar 

  7. Jin F, Prestage GP et al (2006) Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis 194(5):561–570

    Article  PubMed  Google Scholar 

  8. Jones CA, Cunningham AL (2004) Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 11(1):12–17

    PubMed  Google Scholar 

  9. Lu Z, Brans R et al (2009) High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol 129(5):1174–1184

    Article  CAS  PubMed  Google Scholar 

  10. Paz-Bailey G, Ramaswamy M et al (2007) Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect 83(1):16–22

    Article  CAS  PubMed  Google Scholar 

  11. Stanberry LR, Spruance SL et al (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347(21):1652–1661

    Article  CAS  PubMed  Google Scholar 

  12. Whitley RJ, Roizman B (2001) Herpes simplex virus infections. Lancet 357(9267):1513–1518

    Article  CAS  PubMed  Google Scholar 

  13. Yao F, Eriksson E (1999) A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant. Hum Gene Ther 10(11):1811–1818

    Article  CAS  PubMed  Google Scholar 

  14. Yao F, Eriksson E (2002) Inhibition of herpes simplex virus type 2 (HSV-2) viral replication by the dominant negative mutant polypeptide of HSV-1 origin binding protein. Antiviral Res 53(2):127–133

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Fachgebiet Dermatologie, Umweltmedizin und Gesundheitstheorie, Universität Osnabrück, Sedanstr. 115, 49090, Osnabrück, Deutschland

    R. Brans

Authors
  1. R. Brans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Brans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brans, R. Evaluation eines dominant-negativen rekombinanten Herpes-simplex-Virus (HSV) Typ 1 als Impfstoff gegen Herpes genitalis bei Mäusen und Meerschweinchen. Hautarzt 61, 1073–1078 (2010). https://doi.org/10.1007/s00105-010-2075-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-010-2075-8

Schlüsselwörter

Keywords

Search

Navigation